Tenocyclidine API Manufacturers
compare suppliers & get competitive offers
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
Looking for Tenocyclidine API 21500-98-1?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Tenocyclidine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Tenocyclidine
- Synonyms:
- TCP , tetrahydrocannabinol
- Cas Number:
- 21500-98-1
- DrugBank number:
- DB01520
- Unique Ingredient Identifier:
- 8BQ45Q6VCL
About Tenocyclidine
You can find a short description about Tenocyclidine here. Tenocyclidine (TCP, thienyl cyclohexylpiperidine) is a dissociative anesthetic drug with stimulant and hallucinogenic effects. It is more potent than phencyclidine and hence, this drug was classified under the schedule 1 in 1970.
Check who is selling Tenocyclidine in the overview above.
Tenocyclidine is a type of Psychopharmaceuticals
Psychopharmaceuticals are a crucial subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that are designed to treat mental health disorders. These medications play a vital role in managing various psychiatric conditions, including depression, anxiety, schizophrenia, bipolar disorder, and attention-deficit/hyperactivity disorder (ADHD).
Psychopharmaceutical APIs act on the central nervous system (CNS) to alter brain chemistry and neurotransmitter activity. They can modulate the levels of neurotransmitters such as serotonin, dopamine, and norepinephrine, which are involved in regulating mood, cognition, and emotions. By targeting these neurotransmitter systems, psychopharmaceuticals help restore the balance of chemicals in the brain, alleviating symptoms and improving overall mental well-being.
These APIs are developed through rigorous research and development processes, involving extensive clinical trials to ensure their safety and efficacy. Manufacturers adhere to stringent quality standards and regulations to produce psychopharmaceutical APIs that meet the highest pharmaceutical industry standards.
The production of psychopharmaceutical APIs requires advanced technologies and specialized equipment to achieve precise control over the manufacturing process. This ensures the consistency and purity of the APIs, which is crucial for producing reliable and effective psychopharmaceutical formulations.
The market for psychopharmaceuticals is growing rapidly due to increasing awareness and recognition of mental health disorders. With the rising demand, pharmaceutical companies are continuously investing in research and development to discover novel psychopharmaceutical APIs and improve existing formulations.
In conclusion, psychopharmaceutical APIs form a vital subcategory of pharmaceutical ingredients used to treat mental health disorders. These medications act on the central nervous system to modulate neurotransmitter activity and restore the balance of brain chemistry. The development and manufacturing of psychopharmaceutical APIs require advanced technologies and adherence to stringent quality standards. With the growing demand for mental health treatments, the psychopharmaceutical market continues to evolve, offering new therapeutic options for patients in need.
Tenocyclidine (Psychopharmaceuticals), classified under Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
